Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 19/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 18/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 18/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 18/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 11/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 11/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 11/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 11/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 11/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 11/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 11/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2143881 | 0.76 | HDAC3 (0.40) | HDAC6HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL2144010 | 0.73 | HDAC3 (0.48) | HDAC6HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL1367543 | 0.72 | HDAC6 (0.41) | HDAC6HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL4076375 | 0.69 | HDAC6 (0.41) | HDAC6HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL2145828 | 0.69 | HDAC1 (0.45) | HDAC6HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL16566459 | 0.68 | HDAC6 (0.41) | HDAC6HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL1366166 | 0.65 | HDAC1 (0.44) | HDAC6HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL1365588 | 0.65 | HDAC1 (0.44) | HDAC6HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL1366165 | 0.65 | HDAC1 (0.44) | HDAC6HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL1366117 | 0.65 | HDAC1 (0.45) | HDAC6HDAC3HDAC1HDAC2HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150080325-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | ENVIVO PHARMACEUTICALS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-20110288070-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | FMR LLC | 2011-11-24 | — | — | US | disclosed |
| EP-2343286-A1 | Dibenzo[b,f][1,4]oxazepine derivatives as inhibitors of histone deacetylase | Methylgene, Inc. (CA) | 2011-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288070-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC5, HDAC2 | HDAC6 9/4885HDAC3 14/4885HDAC1 1/4885 |
| US-20150080325-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC5, HDAC2 | HDAC6 9/4885HDAC3 14/4885HDAC1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.